| Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV A Stukalov, V Girault, V Grass, O Karayel, V Bergant, C Urban, DA Haas, ... Nature 594 (7862), 246-252, 2021 | 587 | 2021 |
| Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing J Zecha, CY Lee, FP Bayer, C Meng, V Grass, J Zerweck, K Schnatbaum, ... Molecular & Cellular Proteomics 19 (9), 1503-1522, 2020 | 91 | 2020 |
| ADAM10 and ADAM17 promote SARS‐CoV‐2 cell entry and spike protein‐mediated lung cell fusion G Jocher, V Grass, SK Tschirner, L Riepler, S Breimann, T Kaya, ... EMBO reports 23 (6), e54305, 2022 | 70 | 2022 |
| Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread S Ambike, CC Cheng, M Feuerherd, S Velkov, D Baldassi, SQ Afridi, ... Nucleic Acids Research 50 (1), 333-349, 2022 | 49 | 2022 |
| Disruption of disulfides within RBD of SARS‐CoV‐2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs M Manček‐Keber, I Hafner‐Bratkovič, D Lainšček, M Benčina, T Govednik, ... The FASEB Journal 35 (6), 2021 | 48 | 2021 |
| Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection KI Wagner, LM Mateyka, S Jarosch, V Grass, S Weber, K Schober, ... Cell reports 38 (2), 2022 | 23 | 2022 |
| Cross-species analysis of viral nucleic acid interacting proteins identifies TAOKs as innate immune regulators FL Pennemann, A Mussabekova, C Urban, A Stukalov, LL Andersen, ... Nature Communications 12 (1), 7009, 2021 | 22 | 2021 |
| Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases V Bergant, S Yamada, V Grass, Y Tsukamoto, T Lavacca, K Krey, ... The EMBO journal 41 (17), e111608, 2022 | 20 | 2022 |
| Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein HL Svilenov, J Sacherl, A Reiter, LS Wolff, CC Cheng, M Stern, V Grass, ... Antiviral Research 196, 105197, 2021 | 17 | 2021 |
| Adaptation to host cell environment during experimental evolution of Zika virus V Grass, E Hardy, K Kobert, SR Talemi, E Décembre, C Guy, PV Markov, ... Communications Biology 5 (1), 1115, 2022 | 6 | 2022 |
| Systematic analysis of RNAi-accessible SARS-CoV-2 replication steps identifies ORF1 as promising target S Ambike, C Cheng, S Afridi, M Feuerherd, P Hagen, V Grass, O Merkel, ... | 5 | 2020 |
| Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV. bioRxiv. 2020; 1: 1 A Stukalov, V Girault, V Grass, V Bergant, O Karayel, C Urban, DA Haas, ... Google Scholar, 0 | 5 | |
| SARS-CoV-2 CD8+ T cell killing assays using replicating viruses and transgenic antigens LM Mateyka, V Grass, A Pichlmair, DH Busch, E D’Ippolito STAR protocols 3 (4), 101699, 2022 | 3 | 2022 |
| Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors mediating cytotoxicity of virus-infected target cells in non-severe COVID-19 KI Wagner, LM Mateyka, S Jarosch, V Grass, S Weber, K Schober, ... medRxiv, 2021.07. 20.21260845, 2021 | 2 | 2021 |
| MDM2 Influences ACE2 Stability and SARS-CoV-2 Uptake Q Emslander, K Krey, S Hamad, S Maidl, L Oubraham, J Hesse, A Henrici, ... Viruses 15 (8), 1763, 2023 | 1 | 2023 |
| Engineered, nucleocytoplasmic shuttling Cas13d enables highly efficient cytosolic RNA targeting C Gruber, L Krautner, V Bergant, V Grass, Z Ma, L Rheinemann, A Krus, ... Cell Discovery 10 (1), 42, 2024 | | 2024 |
| Treatment of coronavirus infections using sam cycle inhibitors A Pichlmair, V Bergant, V Grass US Patent App. 18/280,325, 2024 | | 2024 |
| Inhibition of SARS-CoV-2 infection and replication by Petasites hybridus CO2-extract (Ze 339) CA Jakwerth, V Grass, A Erb, A Pichlmair, G Boonen, V Butterweck, ... Biomedicine & Pharmacotherapy 170, 115959, 2024 | | 2024 |
| SARS-CoV-2 productively infects human hepatocytes and induces cell death CC Cheng, C Ko, S Ambike, J Sacherl, S Velkov, BH Liao, R Bester, ... | | 2023 |
| IDENTIFICATION OF HIGHLY FUNCTIONAL AND CYTOTOXIC SARS-COV-2-SPECIFIC CD8+ T CELLS BY ORTHOTOPIC TCR REPLACEMENT ENGINEERING L Mateyka, K Wagner, S Jarosch, V Grass, S Weber, M Hammel, ... Human Gene Therapy, A19-A19, 2022 | | 2022 |
